Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis

A 25-year-old patient treated for relapsing remitting multiple sclerosis (RRMS) with natalizumab had a rapid progression of a low grade squamous intraepithelial lesion to a FIGO stage 1B1 squamous cell carcinoma of the uterine cervix within 2 years. She was treated with radical hysterectomy and pelv...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2019-01, Vol.12 (1), p.59-62
Main Authors: Wan, King Man, Oehler, Martin K.
Format: Article
Language:English
Subjects:
Cancer therapies
Case Report
Case reports
Cell adhesion & migration
Cellular biology
Cervical cancer
Cytokines
Dysplasia
HIV
Human immunodeficiency virus
Human papillomavirus
Immune system
Immunotherapy
Infections
Medical screening
Melanoma
Monoclonal antibodies
Multiple sclerosis
Natalizumab
Nervous system
Radiation therapy
Relapsing remitting multiple sclerosis
Squamous cell carcinoma
Viruses
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 25-year-old patient treated for relapsing remitting multiple sclerosis (RRMS) with natalizumab had a rapid progression of a low grade squamous intraepithelial lesion to a FIGO stage 1B1 squamous cell carcinoma of the uterine cervix within 2 years. She was treated with radical hysterectomy and pelvic lymphadenectomy and subsequently developed a vault recurrence within 2 years. The recurrence was treated with definitive synchronous chemo-radiotherapy and she has been disease free for 7 years. This case and existing evidence on increased risk of developing cervical dysplasia under natalizumab show that MS patients under immunosuppressive therapy require close annual cervical screening with immediate investigation of abnormal test results.
ISSN:1662-6575
1662-6575
DOI:10.1159/000496198